ENANTA PHARMACEUTICALS INC Form SC 13G February 10, 2016

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G**

Under the Securities Exchange Act of 1934

# **Enanta Pharmaceuticals**

(Name of Issuer)

## Common Stock, no par value

(Title of Class of Securities)

#### 29251M106

(CUSIP Number)

#### **December 31, 2015**

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)

[\_] Rule 13d-1(c)

[\_] Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

# **SCHEDULE 13G**

CUSIP	29251M106
No.	

1	Names of Reporting I	Persons				
	Apex Capital Manager	Apex Capital Management				
2	Check the appropriate box if a member of a Group (see instructions)					
	(a) [] (b) []					
3	Sec Use Only					
4	Citizenship or Place of Organization					
	United States					
		5	Sole Voting Power			
	Number of		1,234,383			
	Shares Beneficially	6	Shared Voting Power			
Owned by Each Reporting Person With:		7	Sole Dispositive Power			
			1,234,383			
		8	Shared Dispositive Power			
9	Aggregate Amount B	eneficially Owned by I	Each Reporting Person			
	1,234,383					
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)					
	[]					
11	Percent of class represented by amount in row (9)					
	5.0					
12	Type of Reporting Person (See Instructions)					
	IA					

Page 2 of 5

Item	1.				
(a)	Name of Issuer: Enanta Pharmaceuticals				
<b>(b)</b>	Address of Issuer s Principal Executive Offices: 500 Arsenal St., Watertown, MA 02472				
Item	2.				
(a)	Name of Person Filing: Apex Capital Management				
<b>(b)</b>	Address of Principal Business Office or, if None, Residence: 8163 Old Yankee St. Ste. E, Dayton OH 45458				
(c)	Citizenship: United States				
( <b>d</b> )	Title and Class of Securities: Common Shares, no par value				
(e)	CUSIP No.: 29251M106				
Item	Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	(a)	[_]	Broker or dealer registered under Section 15 of the Act;		
	(b)	[_]	Bank as defined in Section 3(a)(6) of the Act;		
	(c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;		
	(d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940;		
	(e)	[x]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);		
	(f)	[_]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);		
	(g)	[_]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);		
	(h)	[_]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		
	(i)	[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;		
	(j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);		
	(k)	[_]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:		

# Item 4. Ownership

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

(a) Amount Beneficially Owned: 1,234,383

Page 3 of 5

### Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

- (b) Percent of Class: 5%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 1,234,383
  - (ii) Shared power to vote or to direct the vote:
  - (iii) Sole power to dispose or to direct the disposition of: 1,234,383
  - (iv) Shared power to dispose or to direct the disposition of:

## Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

- Item 6. Ownership of more than Five Percent on Behalf of Another Person.
- Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
- Item 8. Identification and classification of members of the group.
- Item 9. Notice of Dissolution of Group.
- Item 10. Certifications.

Page 4 of 5

## Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: 02/10/2016

#### Michael Kalbfleisch

Michael Kalbfleisch, Vice President-Principal

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Page 5 of 5